Difference between revisions of "Vortioxetine-maprotiline"

From Psychiatrienet
Jump to: navigation, search
(3 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
| to = maprotiline
 
| to = maprotiline
 
| stop =  
 
| stop =  
* '''Day 1:''' reduce dosage of vortioxetine to 5 mg/day.
+
{{stopVortioxetine}}<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
* '''Day 7:''' stop administration of vortioxetine.
 
 
| start =  
 
| start =  
* '''Day 8:''' start administration of maprotiline in a normal dosage of 25 mg/day.
+
* '''Day 9:''' start administration of maprotiline in a low dosage of 25 mg/day.
* '''Day 15:''' increase dosage of maprotiline.  
 
 
| info =  
 
| info =  
 +
* {{theorSS}}
 
}}
 
}}

Revision as of 15:09, 4 November 2015

Vortioxetine
Type Antidepressant
Group SMS
links
Medscape Vortioxetine
PubChem 9966051
PubMed Vortioxetine
Kompas (Dutch) Vortioxetine
Wikipedia Vortioxetine
Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline

Switch medication from vortioxetine to maprotiline.[1] [2]

Nietinrijdenbord.png Stop vortioxetine
  • Day 1: reduce dosage of vortioxetine to 5 mg/day.
  • Day 8: stop administration of vortioxetine.[3] [4]
Eenrichtingbord.png Start maprotiline
  • Day 9: start administration of maprotiline in a low dosage of 25 mg/day.
Infobord.png More information
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54
  4. KNMP; Informatorium Medicamentorum 2023; Monografie "vortioxetine" (Dutch)
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.